Fig. 7.

Anticancer immune response in the tumor and TDLNs. A, B M1-like macrophages (F4/80⁺ CD86⁺), M2-like macrophages (F4/80⁺CD206⁺) in tumor tissue(n = 5). C M1-like macrophages (F4/80⁺ CD86⁺) in TDLN (n = 3). D, E CD3⁺CD4⁺ and CD3⁺CD8⁺ T cells in TDLN (n = 3). F, G Activated CD4 ⁺and CD8⁺ lymphocytes in TDLN (CD4⁺IFNγ⁺, CD8⁺IFNγ⁺) (n = 3). H Percentages of proliferation in CD8 lymphocytes in TDLN (CD8⁺ki67⁺) (n = 3). I, J CD3⁺CD4⁺and CD3⁺CD8⁺ T cells in tumor tissue(n = 5). K–N Activated CD4 and CD8 lymphocytes in tumors tissue (CD4⁺IFNγ⁺, CD4⁺CD69⁺.CD8⁺IFNγ⁺, CD8⁺CD69⁺) (n = 5). O Percentages of proliferation in CD8 lymphocytes in tumor tissue (CD8⁺ki67⁺) (n = 5). P Percentages of Tregs (CD4⁺FOXP3⁺) in tumor tissue (n = 5). Q, R ELISA analysis of IFN-γ and TNF-α in tumor tissue(n = 5). Data was presented by the mean ± SD. *P < 0.05; **P < 0.01; ***P < 0.001; ****P < 0.0001